Citations

Showing 10 of 108119 citations.

Tbo-filgrastim versus filgrastim for stem cell mobilization and engraftment in autologous hematopoietic stem cell transplant patients: A retrospective review
Potter, Ashley , Beck, Bradley, Ngorsuraches, Surachat , Beck, Bradley

Mayo Clinic

Journal of Oncology Pharmacy Practice | March 9, 2019 | Volume: 26 | Issue: 1 | Pages: 23-28

10.1177/1078155219833444 | PMID 30854925 Get It

Introduction Filgrastim, a granulocyte colony-stimulating factor, is commonly used in autologous hematopoietic stem cell transplants (HSCTs) to assist with peripheral blood progenitor cell (PBPC) collection and to support stem cell engraftment. In the United States, tbo-filgrastim is approved under its own Biologic License Application and is limited to a single indication excluding the HSCT population. Methods Approximately one year after a system-wide formulary change to tbo-filgrastim for all on- and off-label indications, our institution conducted an IRB-approved retrospective comparison of tbo-filgrastim to filgrastim in the autologous HSCT setting. The study included 71 patients who received an autologous HSCT from 1 January 2013 to 31 December 2016 with a documented administration of tbo-filgrastim or filgrastim. Results There were no statistically significant differences noted on CD34 + counts during stem cell mobilization, neutrophil engraftment, infection rates during the engraftment phase, nor duration of hospitalization during the engraftment phase. More patients in the tbo-filgrastim group received plerixafor per protocol resulting in more patients meeting their PBPC collection goal in one day with fewer collection days overall, a result potentially confounded by institutional protocol changes. Utilizing tbo-filgrastim offered an average cost savings per patient of $2664.26 ($1907.33 for PBPC mobilization and $756.93 for stem cell engraftment) when comparing dollars spent on granulocyte colony-stimulating factor products only. Conclusion Tbo-filgrastim demonstrates comparable efficacy with a cost savings benefit compared to filgrastim for autologous PBPC mobilization and stem cell engraftment.
Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model
Thirukkumaran, Chandini M. , Shi, Zhong Qiao, Nuovo, Gerard J. , Luider, Joanne, Dong, Yuan , Mostafa, Ahmed , Thakur, Satbir , Gratton, Kathy, Yang, Ailian, Chin, Alex , Jiménez‐Zepeda, Víctor H. , Stewart, Douglas A. , Chesi, Marta , Bergsagel, P. Leif , Morris, Don , Bergsagel, P. Leif , Mostafa, Ahmed A , Stewart, Douglas , Chesi, Marta , Morris, Don , Nuovo, Gerard J , Kopciuk, Karen A. , Coffey, Matt C.

Mayo Clinic

Blood Advances | March 8, 2019 | Volume: 3 | Issue: 5 | Pages: 797-812

10.1182/bloodadvances.2018025593 | PMID 30850386 Get It

Abstract The oncolytic reovirus (RV) has demonstrated clinical efficacy and minimal toxicity in a variety of cancers, including multiple myeloma (MM). MM is a malignancy of plasma cells that is considered treatable but incurable because of the 90% relapse rate that is primarily from drug resistance. The systemic nature of MM and the antitumor immunosuppression by its tumor microenvironment presents an ongoing therapeutic challenge. In the present study, we demonstrate that RV synergizes with the standard-of-care MM drug bortezomib (BTZ) and, importantly, enhances its therapeutic potential in therapy-resistant human MM cell lines in vitro. Using the syngeneic Vk*MYC BTZ-resistant immunocompetent transplantable MM murine model, we also demonstrate that mice harboring BTZ-insensitive MM tumors respond to the RV/BTZ combination treatment in terms of decreased tumor burden and improved overall survival (P < .00001). We demonstrate that BTZ augments RV replication in tumor-associated endothelial cells and myeloma cells, leading to enhanced viral delivery and thereby stimulating cytokine release, immune activity, apoptosis, and reduction of the MM-associated immune suppression. We conclude that combined RV/BTZ is an attractive therapeutic strategy with no safety signals for the treatment of MM.
Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated m
Somlo, George, Frankel, Paul , Luu, Thehang, Cynthia, X. , García, Agustin A. , Cigler, Tessa, Cream, Leah, Harvey, Harold A., Nanda, Rita , Chew, Helen K. , Moynihan, Timothy J. , Hurria, Arti , Chen, Alice P. , Arun, Banu , Sparano, Joseph A. , Vahdat, Linda T. , Goetz, Matthew P. , Mortimer, Joanne , Gandara, David R. , Weitzel, Jeffrey N.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 520-520

10.1200/jco.2015.33.15_suppl.520 Get It

DNA methylation in serum as an independent marker of outcome and treatment response in TBCRC 005: A prospective study in metastatic breast cancer (MBC) patients.
Fackler, Mary Jo , Lopez‐Bujanda, Zoila A. , Jeter, Stacie C., Sokoll, Lori J. , Cope, Leslie , Umbricht, Christopher B. , Euhus, David , Carpenter, John T., Storniolo, Anna Maria , Nanda, Rita , Lopez-Bujanda, Zoila A , Visvanathan, Kala , Zhang, Zhe , Lin, Nancy U. , Carey, Lisa A. , Ingle, James N. , Sukumar, Saraswati , Wolff, Antonio C.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 518-518

10.1200/jco.2015.33.15_suppl.518 Get It

Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study.
Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Gelber, Shari , Schapira, Lidia , Come, Steven E. , Meyer, Meghan E., Tamimi, Rulla M. , Borges, Virginia F. , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 515-515

10.1200/jco.2015.33.15_suppl.515 Get It

Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.
Ellis, Paul Anthony, Barrios, Carlos H. , Eiermann, W., Im, Young‐Hyuck , Burris, Howard A. , Strasak, Alexander, Patre, Monika, Perez, Edith A. , Toi, Masakazu , Conte, PierFranco , Martín, Miguel , Pieńkowski, Tadeusz , Pivot, Xavier B.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 507-507

10.1200/jco.2015.33.15_suppl.507 Get It

Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.
Paterson, Alexander , Lew, Danika L., Hayes, Daniel F. , Schubert, Mark, Poznak, Catherine Van , Dees, Elizabeth Claire , Messino, Michael J., Margolis, Jeffrey, Dakhil, Shaker R. , Chew, Helen K. , Livingston, Robert B., Gralow, Julie R. , Barlow, William E. , Stopeck, Alison , Hershman, Dawn L. , Clemons, Mark , Ingle, James N. , Falkson, Carla I. , Elias, Anthony , Hortobágyi, Gabriel N.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 503-503

10.1200/jco.2015.33.15_suppl.503 Get It

Assessment of Employee Susceptibility to Phishing Attacks at US Health Care Institutions
Gordon, William J. , Wright, Adam , Aiyagari, Ranjit , Corbo, Leslie , Glynn, Robert J. , Kadakia, Jigar, Kufahl, Jack, Mazzone, Christina, Noga, James, Parkulo, Mark A. , Sanford, Brad, Scheib, Paul, Parkulo, Mark, Landman, Adam

Mayo Clinic

JAMA Network Open | March 8, 2019 | Volume: 2 | Issue: 3 | Pages: e190393

10.1001/jamanetworkopen.2019.0393 | PMID 30848810 Get It